FY2027 Earnings Estimate for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Research analysts at Leerink Partnrs dropped their FY2027 earnings per share estimates for shares of Ionis Pharmaceuticals in a research report issued on Sunday, November 9th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($2.15) for the year, down from their prior estimate of ($1.60). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2028 earnings at ($0.20) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. The firm had revenue of $157.00 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 45.29%. Ionis Pharmaceuticals’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.95) earnings per share. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Other equities analysts also recently issued reports about the stock. Bank of America lifted their target price on shares of Ionis Pharmaceuticals from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. Citigroup increased their price objective on Ionis Pharmaceuticals from $69.00 to $84.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler increased their target price on shares of Ionis Pharmaceuticals from $70.00 to $77.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Morgan Stanley upped their price objective on shares of Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $84.15.

Ionis Pharmaceuticals Trading Up 0.6%

NASDAQ:IONS traded up $0.47 during trading hours on Wednesday, hitting $72.92. The company had a trading volume of 240,074 shares, compared to its average volume of 1,975,009. Ionis Pharmaceuticals has a 1 year low of $23.95 and a 1 year high of $76.78. The company has a market cap of $11.81 billion, a P/E ratio of -43.02 and a beta of 0.33. The company has a 50-day moving average of $67.95 and a 200 day moving average of $48.95. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IONS. Golden State Wealth Management LLC lifted its stake in Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after purchasing an additional 250 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $25,000. Mather Group LLC. acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth $27,000. Meeder Asset Management Inc. boosted its stake in Ionis Pharmaceuticals by 620.2% in the third quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock valued at $47,000 after acquiring an additional 614 shares in the last quarter. Finally, Allworth Financial LP lifted its stake in Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after buying an additional 517 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Insider Transactions at Ionis Pharmaceuticals

In other news, EVP Shannon L. Devers sold 1,263 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $73.62, for a total transaction of $92,982.06. Following the completion of the sale, the executive vice president directly owned 17,494 shares of the company’s stock, valued at approximately $1,287,908.28. The trade was a 6.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph H. Wender sold 11,200 shares of the stock in a transaction on Friday, October 31st. The shares were sold at an average price of $75.16, for a total value of $841,792.00. Following the completion of the transaction, the director directly owned 64,035 shares in the company, valued at $4,812,870.60. This trade represents a 14.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 924,789 shares of company stock valued at $59,515,499 over the last quarter. Insiders own 2.71% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.